GI
AMLX icon

GAMMA Investing’s Amylyx Pharmaceuticals AMLX Stock Holding History

GAMMA Investing’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33.1K Buy
1,139
+706
+163% +$18.7K ﹤0.01% 2626
2026
Q2 		$7.78K Buy
433
+16
+4% +$247 ﹤0.01% 3307
2026
Q1 		$5.8K Buy
417
+150
+56% +$2.11K ﹤0.01% 3310
2025
Q4 		$3.23K Buy
267
+142
+114% +$1.93K ﹤0.01% 3450
2025
Q3 		$1.7K Buy
+125
New +$1.18K ﹤0.01% 3495
2024
Q2 		– Sell
-35
Closed -$99 – 3448
2024
Q1 		$99 Hold
35
– – ﹤0.01% 3285
2023
Q4 		$560 Buy
+35
New +$536 ﹤0.01% 2939

Other funds holding AMLX

VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GAMMA Investing's AMLX Position: Q3 2026 in Review

GAMMA Investing increased its Amylyx Pharmaceuticals (AMLX) stake by 163% in Q3 2026, buying an estimated $18.7K and bringing the position to 1,139 shares worth $33.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

GAMMA Investing first reported a position in AMLX in Q4 2023 and has held it in 7 quarters since. 6 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • GAMMA Investing held 1,139 shares of Amylyx Pharmaceuticals worth $33.1K as of Q3 2026.
  • GAMMA Investing bought 706 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $18.7K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2626 holding.
  • GAMMA Investing first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 7 quarters since.
  • 6 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.